ArticleNature communications2026
A meta learning and task adaptive approach for drug target affinity prediction.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CBInformax: bioactivity-aware self-supervised molecular representation learning for molecular property and drug-drug interaction prediction.Molecular diversity · 2026Article
- A meta learning and task adaptive approach for drug target affinity prediction.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and robust prediction of drug-target affinity (DTA) plays a critical role in drug discovery. While deep learning has advanced DTA prediction, existing methods struggle with limited training data and poor generalization. In this study, we propose AdaMBind, a novel DTA prediction model based on meta-learning framework with an adaptive task module designed for low-data scenarios. It employs a dynamic "easy-to-hard" task scheduling mechanism to enhance training efficiency and robustness. Experimental results on three benchmark datasets demonstrate that AdaMBind outperforms 8 baseline models in predicting affinity for unseen targets, particularly under few-shot conditions. Under stringent data constraints, the model successfully identifies high-affinity compounds for ESR and TP53, achieving outstanding virtual screening performance. Furthermore, when applied to inhibitor discovery against FLT3 for acute myeloid leukemia, AdaMBind successfully identified candidate compounds with potent inhibitory activity, as verified by preliminary experimental assays. In summary, AdaMBind provides a robust framework for few-shot DTA prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.